A comparison of randomized phase 3 trials using a melphalan and prednisone backbone
| . | Median PFS (mo) . | Median OS (mo) . |
|---|---|---|
| MPT10 (meta-analysis) | 21 | 39 |
| MPT-T (E1A06) | 21 | 53 |
| MPT-T (HOVON)26 | 20 | 49 |
| MPR (MM-015)9 | 14 | 52 |
| MPR-R (E1A06) | 19 | 48 |
| MPR-R (HOVON) | 22 | 50 |
| MPR-R (MM-015)9 | 31 | 56 |
| MPV (Vista)2 | 24 | 56 |
| . | Median PFS (mo) . | Median OS (mo) . |
|---|---|---|
| MPT10 (meta-analysis) | 21 | 39 |
| MPT-T (E1A06) | 21 | 53 |
| MPT-T (HOVON)26 | 20 | 49 |
| MPR (MM-015)9 | 14 | 52 |
| MPR-R (E1A06) | 19 | 48 |
| MPR-R (HOVON) | 22 | 50 |
| MPR-R (MM-015)9 | 31 | 56 |
| MPV (Vista)2 | 24 | 56 |